New York's attorney general says a drug manufacturer has been ordered to halt plans to discontinue its widely used Alzheimer's medication, allegedly in an effort to drive patients to a newer patented drug. Attorney General Eric Schneiderman alleges anti-trust and state law violations by Dublin-based Actavis PLC and New York subsidiary Forest Laboratories in an effort to avoid losses from cheaper generic alternatives coming out next year.